Endoscopic Placement of Metal Stent in Patients With Cancer-Related Bowel Obstruction

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00004911
Recruitment Status : Completed
First Posted : May 14, 2003
Last Update Posted : June 6, 2012
National Cancer Institute (NCI)
Information provided by (Responsible Party):
Northwestern University

March 7, 2000
May 14, 2003
June 6, 2012
January 2000
February 2003   (Final data collection date for primary outcome measure)
Not Provided
Not Provided
Complete list of historical versions of study NCT00004911 on Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
Endoscopic Placement of Metal Stent in Patients With Cancer-Related Bowel Obstruction
A Pilot Phase I/II Trial of Enteral Wallstents for Colonic Obstruction in the Setting of Malignancy

RATIONALE: The use of endoscopy to place a metal stent in the large intestine is less invasive than surgery for treating cancer-related bowel obstruction and may have fewer side effects and improve recovery.

PURPOSE: Phase I/II trial to study the effectiveness of endoscopic placement of a metal stent in treating patients who have cancer-related bowel obstruction.


  • Determine the objective response and clinical outcome in patients with colonic obstruction secondary to malignancy treated with enteral Wallstents.
  • Evaluate the efficacy and safety of this treatment in these patients.
  • Evaluate the quality of life of these patients after enteral Wallstent placement.

OUTLINE: All patient undergo a colonoscopy, followed by placement of an enteral Wallstent through an endoscope under fluoroscopic guidance into the large intestine.

Quality of life is assessed at 48 hours and 6 months after the procedure.

Patients are followed at 48 hours, 30 days, 6 months, and then yearly thereafter until death.

PROJECTED ACCRUAL: A total of 20 patients will be accrued for this study.

Phase 1
Phase 2
Primary Purpose: Supportive Care
  • Colorectal Cancer
  • Constipation, Impaction, and Bowel Obstruction
  • Gastric Cancer
  • Gastrointestinal Carcinoid Tumor
  • Gastrointestinal Stromal Tumor
  • Quality of Life
  • Small Intestine Cancer
  • Procedure: bowel obstruction management
  • Procedure: quality-of-life assessment
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by Identifier (NCT Number) in Medline.
Not Provided
Not Provided
February 2003
February 2003   (Final data collection date for primary outcome measure)


  • Endoscopically confirmed localized tumor as the cause of colonic obstruction

    • All primary tumor types are eligible
  • No prior colonic Wallstents
  • Must have symptoms of gastrointestinal obstruction, including:

    • Inability to move bowels, absence of flatus, nausea/vomiting, abdominal pain, or diarrhea



  • 18 and over

Performance status:

  • ECOG 0-3

Life expectancy:

  • Not specified


  • Platelet count greater than 50,000/mm^3


  • INR no greater than 1.5 times upper limit of normal


  • Not specified


  • No cardiac condition


  • Not pregnant or nursing
  • Fertile patients must use effective contraception
  • No significant active infection (e.g., pneumonia, peritonitis, wound abscess) that would preclude endoscopy
  • No other serious concurrent illness
  • No uncontrolled metabolic disease (e.g., diabetes or hypothyroidism)
  • No dementia, psychiatric disorder, or altered mental status that would preclude compliance
  • History of other neoplastic disease allowed
  • Veterans Administration patients are not eligible


Biologic therapy:

  • Not specified


  • Prior or concurrent chemotherapy allowed

Endocrine therapy:

  • Not specified


  • Prior or concurrent radiotherapy allowed


  • At least 3 weeks since prior surgery and recovered
Sexes Eligible for Study: All
18 Years and older   (Adult, Senior)
Contact information is only displayed when the study is recruiting subjects
United States
NU 98CC3
Not Provided
Not Provided
Northwestern University
Northwestern University
National Cancer Institute (NCI)
Study Chair: Willis G. Parsons, MD, PC Robert H. Lurie Cancer Center
Northwestern University
May 2012

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP